August 1, 2012—Octapharma USA’s octagam 5% immune globulin intravenous (IGIV) therapy is now available at sub-340B pricing to participants in the Apexus/340B Prime Vendor Program (PVP).
Apexus Director of Contract Services John Barnes made the announcement in a July 30 email to PVP participants.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)